$IBIO “Immunization with more conserved sequences, such as the N protein, is expected to generate T-cells that could clear spike protein variant viruses in addition to the original virus,” said Martin Brenner, DVM. Ph.D., iBio’s CSO. “The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine.” https://ir.ibioinc.com/news-events/press-releases/detail/157/ibio-reports-successful-covid-19-vaccine-toxicology-study